The DOI matches its Crossref record; 69 of the 69 references it cites were found in a registry or an index.
Non-Small-Cell Lung Cancer in 2022: A Review for General Practitioners in Oncology
Open accessAbstract
Lung cancer is the leading cause of cancer death in Canada and a significant cause of morbidity for patients and their loved ones. There have been rapid advances in preventing, screening and treating this disease. Here, we present a contemporary review of treatment of non-small cell lung cancer in Canada based on current best practices. The focus of this review is to highlight recent data in screening for lung cancer, management of patients with early and locally-advanced non-small cell lung cancer, as well as management of patients with metastatic disease. There is a special focus on the incorporation of immunotherapy into practice and its associated toxicities.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay-Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,256
Early Palliative Care for Patients with Metastatic Non–Small-Cell Lung Cancer
Temel, J. S., Greer, J. A., Muzikansky, A., Gallagher, E. R., Admane, S., Jackson, V. A., Dahlin, C. M., Blinderman, C. D., Jacobsen, J., Pirl, W. F., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1000678 · Cited by 7,482
Pembrolizumab plus chemotherapy in metastatic non–small-cell lung cancer
Gandhi, L., Rodríguez-Abreu, D., Gadgeel, S., Esteban, E., Felip, E., De Angelis, F., Domine, M., Clingan, P., Hochmair, M. J., Powell, S. F., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1801005 · Cited by 6,607 · cited 1×
“In this study, the chemotherapy consisted of carboplatin and a taxane [59].”
Osimertinib in Untreated EGFR -Mutated Advanced Non–Small-Cell Lung Cancer
Soria, J.-C., Ohe, Y., Vansteenkiste, J., Reungwetwattana, T., Chewaskulyong, B., Lee, K. H., Dechaphunkul, A., Imamura, F., Nogami, N., Kurata, T., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1713137 · Cited by 5,508 · cited 1×
“Osimertinib, a third-generation oral EGFR–TKI, selectively binds both EGFR driver mutations and EGFR T790M resistance mutations [16].”
BackgroundGoldstraw, P., Chansky, K., Crowley, J., Rami-Porta, R., Asamura, H., Eberhardt, W. E. E., Nicholson, A. G., Groome, P., Mitchell, A., Bolejack, V., et al. (2016) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2015.09.009 · Cited by 4,607
Durvalumab after chemoradiotherapy in stage III non–small-cell lung cancer
Antonia, S. J., Villegas, A., Daniel, D., Vicente, D., Murakami, S., Hui, R., Yokoi, T., Chiappori, A., Lee, K. H., de Wit, M., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1709937 · Cited by 4,593
Brahmer, J. R., Lacchetti, C., Schneider, B. J., Atkins, M. B., Brassil, K. J., Caterino, J. M., Chau, I., Ernstoff, M. S., Gardner, J. M., Ginex, P., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.77.6385 · Cited by 3,713
Reduced Lung-Cancer Mortality with Volume CT Screening in a Randomized Trial
de Koning, H. J., van der Aalst, C. M., de Jong, P. A., Scholten, E. T., Nackaerts, K., Heuvelmans, M. A., Lammers, J.-W. J., Weenink, C., Yousaf-Khan, U., Horeweg, N., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1911793 · Cited by 3,624
Epidermal growth factor receptor mutations in lung cancer
Sharma, S. V., Bell, D. W., Settleman, J., & Haber, D. A. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2088 · Cited by 3,170
Overall Survival with Osimertinib in Untreated, EGFR -Mutated Advanced NSCLC
Ramalingam, S. S., Vansteenkiste, J., Planchard, D., Cho, B. C., Gray, J. E., Ohe, Y., Zhou, C., Reungwetwattana, T., Cheng, Y., Chewaskulyong, B., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1913662 · Cited by 2,914
Global patterns of cancer incidence and mortality rates and trends
Jemal, A., Center, M. M., DeSantis, C., & Ward, E. M. (2010) · Cancer Epidemiology, Biomarkers & Prevention · doi:10.1158/1055-9965.epi-10-0437 · Cited by 2,778
Wang, D. Y., Salem, J.-E., Cohen, J. V., Chandra, S., Menzer, C., Ye, F., Zhao, S., Das, S., Beckermann, K. E., Ha, L., et al. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2018.3923 · Cited by 2,674
Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group.
Pignon, J.-P., Tribodet, H., Scagliotti, G. V., Douillard, J.-Y., Shepherd, F. A., Stephens, R. J., Dunant, A., Torri, V., Rosell, R., Seymour, L., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.13.9030 · Cited by 2,642 · cited 2×
“The benefit of adjuvant chemotherapy increased to 13% for stage III lung cancers when compared with no chemotherapy [14].”
BackgroundHaanen, J. B. A. G., Carbonnel, F., Robert, C., Kerr, K. M., Peters, S., Larkin, J., & Jordan, K. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx225 · Cited by 2,367
Immune-related adverse events with immune checkpoint blockade: a comprehensive review
Michot, J. M., Bigenwald, C., Champiat, S., Collins, M., Carbonnel, F., Postel-Vinay, S., Berdelou, A., Varga, A., Bahleda, R., Hollebecque, A., et al. (2016) · European Journal of Cancer · doi:10.1016/j.ejca.2015.11.016 · Cited by 2,127
Crizotinib in ROS1-Rearranged Non–Small-Cell Lung Cancer
Shaw, A. T., Ou, S.-H. I., Bang, Y.-J., Camidge, D. R., Solomon, B. J., Salgia, R., Riely, G. J., Varella-Garcia, M., Shapiro, G. I., Costa, D. B., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1406766 · Cited by 1,964 · cited 1×
“Evidence supporting the use of crizotinib for ROS1 positive NSCLC is based on early phase clinical trials demonstrating an ORR of 72%, with median duration of response of 25 months [47].”
MethodAupérin, A., Le Péchoux, C., Rolland, E., Curran, W. J., Furuse, K., Fournel, P., Belderbos, J., Clamon, G., Ulutin, H. C., Paulus, R., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.2543 · Cited by 1,878
Osimertinib in Resected EGFR -Mutated Non–Small-Cell Lung Cancer
Wu, Y.-L., Tsuboi, M., He, J., John, T., Grohe, C., Majem, M., Goldman, J. W., Laktionov, K., Kim, S.-W., Kato, T., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2027071 · Cited by 1,798
KRAS G12C Inhibition with Sotorasib in Advanced Solid Tumors
Hong, D. S., Fakih, M. G., Strickler, J. H., Desai, J., Durm, G. A., Shapiro, G. I., Falchook, G. S., Price, T. J., Sacher, A., Denlinger, C. S., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1917239 · Cited by 1,733
Atezolizumab for First-Line Treatment of PD-L1–Selected Patients with NSCLC
Herbst, R. S., Giaccone, G., de Marinis, F., Reinmuth, N., Vergnenegre, A., Barrios, C. H., Morise, M., Felip, E., Andric, Z., Geater, S., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1917346 · Cited by 1,664
Smoking prevalence and cigarette consumption in 187 countries, 1980-2012
Ng, M., Freeman, M. K., Fleming, T. D., Robinson, M., Dwyer-Lindgren, L., Thomson, B., Wollum, A., Sanman, E., Wulf, S., Lopez, A. D., et al. (2014) · JAMA · doi:10.1001/jama.2013.284692 · Cited by 1,576
ROS1 Rearrangements Define a Unique Molecular Class of Lung Cancers
Bergethon, K., Shaw, A. T., Ignatius Ou, S.-H., Katayama, R., Lovly, C. M., McDonald, N. T., Massion, P. P., Siwak-Tapp, C., Gonzalez, A., Fang, R., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.35.6345 · Cited by 1,555
Felip, E., Altorki, N., Zhou, C., Csőszi, T., Vynnychenko, I., Goloborodko, O., Luft, A., Akopov, A., Martinez-Marti, A., Kenmotsu, H., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)02098-5 · Cited by 1,486
Albain, K. S., Swann, R. S., Rusch, V. W., Turrisi, A. T., Shepherd, F. A., Smith, C., Chen, Y., Livingston, R. B., Feins, R. H., Gandara, D. R., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60737-6 · Cited by 1,470
Rizvi, N. A., Mazières, J., Planchard, D., Stinchcombe, T. E., Dy, G. K., Antonia, S. J., Horn, L., Lena, H., Minenza, E., Mennecier, B., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)70054-9 · Cited by 1,415
Reck, M., Rodríguez-Abreu, D., Robinson, A. G., Hui, R., Csőszi, T., Fülöp, A., Gottfried, M., Peled, N., Tafreshi, A., Cuffe, S., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.21.00174 · Cited by 1,159
Gadgeel, S., Rodríguez-Abreu, D., Speranza, G., Esteban, E., Felip, E., Dómine, M., Hui, R., Hochmair, M. J., Clingan, P., Powell, S. F., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.03136 · Cited by 1,116
First-Line Lorlatinib or Crizotinib in Advanced ALK -Positive Lung Cancer
Shaw, A. T., Bauer, T. M., de Marinis, F., Felip, E., Goto, Y., Liu, G., Mazieres, J., Kim, D.-W., Mok, T., Polli, A., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2027187 · Cited by 1,099
Yang, J. C.-H., Sequist, L. V., Geater, S. L., Tsai, C.-M., Mok, T. S. K., Schuler, M., Yamamoto, N., Yu, C.-J., Ou, S.-H. I., Zhou, C., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00026-1 · Cited by 1,002 · cited 1×
“A post hoc analysis of LUX-LUNG 3 and LUX-LUNG 6 demonstrated a benefit with the use of afatinib for uncommon mutations [34].”
MethodBrigatinib versus Crizotinib in ALK -Positive Non–Small-Cell Lung Cancer
Camidge, D. R., Kim, H. R., Ahn, M.-J., Yang, J. C.-H., Han, J.-Y., Lee, J.-S., Hochmair, M. J., Li, J. Y.-C., Chang, G.-C., Lee, K. H., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1810171 · Cited by 980
Ettinger, D. S., Wood, D. E., Aisner, D. L., Akerley, W., Bauman, J. R., Bharat, A., Bruno, D. S., Chang, J. Y., Chirieac, L. R., D’Amico, T. A., et al. (2021) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2021.0013 · Cited by 948
Lindeman, N. I., Cagle, P. T., Aisner, D. L., Arcila, M. E., Beasley, M. B., Bernicker, E. H., Colasacco, C., Dacic, S., Hirsch, F. R., Kerr, K., et al. (2018) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2017-0388-cp · Cited by 936
Hida, T., Nokihara, H., Kondo, M., Kim, Y. H., Azuma, K., Seto, T., Takiguchi, Y., Nishio, M., Yoshioka, H., Imamura, F., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)30565-2 · Cited by 911
Wang, Y., Zhou, S., Yang, F., Qi, X., Wang, X., Guan, X., Shen, C., Duma, N., Vera Aguilera, J., Chintakuntlawar, A., et al. (2019) · JAMA Oncology · doi:10.1001/jamaoncol.2019.0393 · Cited by 862
Sezer, A., Kilickap, S., Gümüş, M., Bondarenko, I., Özgüroğlu, M., Gogishvili, M., Turk, H. M., Cicin, I., Bentsion, D., Gladkov, O., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00228-2 · Cited by 789
Ganti, A. K., Klein, A. B., Cotarla, I., Seal, B., & Chou, E. (2021) · JAMA Oncology · doi:10.1001/jamaoncol.2021.4932 · Cited by 770
Mok, T., Camidge, D. R., Gadgeel, S. M., Rosell, R., Dziadziuszko, R., Kim, D.-W., Pérol, M., Ou, S.-H. I., Ahn, J. S., Shaw, A. T., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.04.478 · Cited by 686
Borghaei, H., Gettinger, S., Vokes, E. E., Chow, L. Q. M., Burgio, M. A., de Castro Carpeno, J., Pluzanski, A., Arrieta, O., Frontera, O. A., Chiari, R., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.20.01605 · Cited by 656
Park, K., Haura, E. B., Leighl, N. B., Mitchell, P., Shu, C. A., Girard, N., Viteri, S., Han, J.-Y., Kim, S.-W., Lee, C. K., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.21.00662 · Cited by 655
Bradley, J. D., Hu, C., Komaki, R. R., Masters, G. A., Blumenschein, G. R., Schild, S. E., Bogart, J. A., Forster, K. M., Magliocco, A. M., Kavadi, V. S., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.01162 · Cited by 591
van Iersel, C. A., de Koning, H. J., Draisma, G., Mali, W. P. T. M., Scholten, E. T., Nackaerts, K., Prokop, M., Habbema, J. D. F., Oudkerk, M., & van Klaveren, R. J. (2007) · International Journal of Cancer · doi:10.1002/ijc.22134 · Cited by 494
Vokes, E. E., Herndon, J. E., Kelley, M. J., Cicchetti, M. G., Ramnath, N., Neill, H., Atkins, J. N., Watson, D. M., Akerley, W., & Green, M. R. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.07.3569 · Cited by 478
Shankar, B., Zhang, J., Naqash, A. R., Forde, P. M., Feliciano, J. L., Marrone, K. A., Ettinger, D. S., Hann, C. L., Brahmer, J. R., Ricciuti, B., et al. (2020) · JAMA Oncology · doi:10.1001/jamaoncol.2020.5012 · Cited by 474
Faivre-Finn, C., Vicente, D., Kurata, T., Planchard, D., Paz-Ares, L., Vansteenkiste, J. F., Spigel, D. R., Garassino, M. C., Reck, M., Senan, S., et al. (2021) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2020.12.015 · Cited by 459
Hanna, N. H., Schneider, B. J., Temin, S., Baker, S., Brahmer, J., Ellis, P. M., Gaspar, L. E., Haddad, R. Y., Hesketh, P. J., Jain, D., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.03022 · Cited by 456
Haanen, J. B. A. G., Carbonnel, F., Robert, C., Kerr, K. M., Peters, S., Larkin, J., & Jordan, K. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy162 · Cited by 431
Genetic alterations defining NSCLC subtypes and their therapeutic implications
Pikor, L. A., Ramnarine, V. R., Lam, S., & Lam, W. L. (2013) · Lung Cancer · doi:10.1016/j.lungcan.2013.07.025 · Cited by 375
Targeting EGFR exon 20 insertion mutations in non-small cell lung cancer
Vyse, S., & Huang, P. H. (2019) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-019-0038-9 · Cited by 370
Pisters, K. M. W., Evans, W. K., Azzoli, C. G., Kris, M. G., Smith, C. A., Desch, C. E., Somerfield, M. R., Brouwers, M. C., Darling, G., Ellis, P. M., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.1226 · Cited by 363
Shaw, A. T., Solomon, B. J., Chiari, R., Riely, G. J., Besse, B., Soo, R. A., Kao, S., Lin, C.-C., Bauer, T. M., Clancy, J. S., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30655-2 · Cited by 358
Camidge, D. R., Kim, H. R., Ahn, M.-J., Yang, J. C. H., Han, J.-Y., Hochmair, M. J., Lee, K. H., Delmonte, A., García Campelo, M. R., Kim, D.-W., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.20.00505 · Cited by 351
Ricciuti, B., Genova, C., De Giglio, A., Bassanelli, M., Dal Bello, M. G., Metro, G., Brambilla, M., Baglivo, S., Grossi, F., & Chiari, R. (2019) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-018-2805-3 · Cited by 345 · cited 1×
“Although the data are mainly retrospective, there may be a group of patients who develop severe or multiple iRAEs who do not need to be retreated and have very good long-term outcomes [69,70].”
BackgroundRothschild, S. I., Zippelius, A., Eboulet, E. I., Savic Prince, S., Betticher, D., Bettini, A., Früh, M., Joerger, M., Lardinois, D., Gelpke, H., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.21.00276 · Cited by 333
Hanna, N. H., Robinson, A. G., Temin, S., Baker, S., Brahmer, J. R., Ellis, P. M., Gaspar, L. E., Haddad, R. Y., Hesketh, P. J., Jain, D., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.20.03570 · Cited by 300
Zhou, C., Ramalingam, S. S., Kim, T. M., Kim, S.-W., Yang, J. C.-H., Riely, G. J., Mekhail, T., Nguyen, D., Garcia Campelo, M. R., Felip, E., et al. (2021) · JAMA Oncology · doi:10.1001/jamaoncol.2021.4761 · Cited by 291
Zhou, C., Kim, S.-W., Reungwetwattana, T., Zhou, J., Zhang, Y., He, J., Yang, J.-J., Cheng, Y., Lee, S.-H., Bu, L., et al. (2019) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(19)30053-0 · Cited by 273
Metabolic networks in mutant KRAS-driven tumours: tissue specificities and the microenvironment
Kerk, S. A., Papagiannakopoulos, T., Shah, Y. M., & Lyssiotis, C. A. (2021) · Nature Reviews Cancer · doi:10.1038/s41568-021-00375-9 · Cited by 237
Recommendations on screening for lung cancer
Canadian Task Force on Preventive Health Care (2016) · Canadian Medical Association Journal · doi:10.1503/cmaj.151421 · Cited by 190
Reck, M., Ciuleanu, T.-E., Cobo, M., Schenker, M., Zurawski, B., Menezes, J., Richardet, E., Bennouna, J., Felip, E., Juan-Vidal, O., et al. (2021) · ESMO Open · doi:10.1016/j.esmoop.2021.100273 · Cited by 186
Smoking Cessation: An Integral Part of Lung Cancer Treatment
Cataldo, J. K., Dubey, S., & Prochaska, J. J. (2010) · Oncology · doi:10.1159/000319937 · Cited by 181
Management of pulmonary toxicity associated with immune checkpoint inhibitors
Delaunay, M., Prévôt, G., Collot, S., Guilleminault, L., Didier, A. P., & Mazières, J. (2019) · European Respiratory Review · doi:10.1183/16000617.0012-2019 · Cited by 113
Sadate, A., Occéan, B., Bérégi, J.-P., Hamard, A., Addala, T., de Forges, H., Fabbro-Péray, P., & Frandon, J. (2020) · European Journal of Cancer · doi:10.1016/j.ejca.2020.04.035 · Cited by 90
Immune Checkpoint Inhibitor–Mediated Diarrhea and Colitis: A Clinical Review
Gong, Z., & Wang, Y. (2020) · JCO Oncology Practice · doi:10.1200/op.20.00002 · Cited by 75
Cressman, S., Lam, S. C., Tammemägi, M. C., Evans, W. K., Leighl, N. B., Regier, D. A., Bolbocean, C., Shepherd, F. A., Tsao, M., Manos, D., et al. (2014) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000283 · Cited by 51
Kunimasa, K., Oka, T., Hara, S., Yamada, N., Oizumi, S., Miyashita, Y., Kamada, R., Funamoto, T., Kawachi, H., Kawamura, T., et al. (2020) · Lung Cancer · doi:10.1016/j.lungcan.2020.10.021 · Cited by 44
Cai, D., Hu, C., Li, L., Deng, S., Yang, J., Han‐Zhang, H., & Li, M. (2019) · Cancer Medicine · doi:10.1002/cam4.2682 · Cited by 41
Interventions for smoking cessation in people diagnosed with lung cancer
Zeng, L., Yu, X., Yu, T., Jianhong, X., & Huang, Y. (2019) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011751.pub3 · Cited by 33
Interventions for smoking cessation in people diagnosed with lung cancer
Zeng, L., Yu, X., Yu, T., Jianhong, X., & Huang, Y. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011751.pub2 · Cited by 28
Reck, M., Spira, A. I., Besse, B., Wolf, J. M., Skoulidis, F., Borghaei, H., Goto, K., Park, K., Griesinger, F., Felip, E., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.08.1730 · Cited by 21
Cited by
Cancer treatment and survivorship statistics, 2025
Wagle, N. S., Nogueira, L., Devasia, T. P., Mariotto, A. B., Yabroff, K. R., Islami, F., Jemal, A., Alteri, R., Ganz, P. A., & Siegel, R. L. (2025) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.70011 · Cited by 261
Metadata
- Authors
- Mithoowani, H., & Febbraro, M.
- Venue
- Current Oncology
- Publisher
- MDPI AG
- Published
- 2022-03-09
- Volume
- 29
- Issue
- 3
- Pages
- 1828-1839
- ISSN
- 1198-0052 (ISSN-L)
- 1718-7729
- OpenAlex
- W4221126421
- Cited by
- 259
- References
- 69
- FWCI
- 32.70
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.